CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results

Urology

Volumn 53, Issue 4, 1999, Pages 757-763

  Klotz, Laurence H ^a,g   Larry Goldenberg, S ^a   Jewett, Michael ^e   Barkin, Jack ^b   Chetner, Michael ^c   Fradet, Yves ^a   Chin, Joseph ^d   Laplante, Suzanne ^f  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

^e UNIVERSITÉ LAVAL   (Canada)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

^g INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYPROTERONE ACETATE; PROSTATE SPECIFIC ANTIGEN;

ADJUVANT THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; SEMINAL VESICLE; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME; TUMOR VOLUME;

ANDROGEN ANTAGONISTS; CHEMOTHERAPY, ADJUVANT; CYPROTERONE ACETATE; DISEASE PROGRESSION; HUMANS; MALE; PREOPERATIVE CARE; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 0033118553     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00616-5     Document Type: Article

References (13)

1. Fair WR, Aprikian AG, Cohen D, et al: Use of neoadjuvant androgen deprivation therapy in clinically localized prostate cancer. Clin Invest Med 16: 516-522, 1993.
2. Van Poppel H, De Ridder D, Elgamal AA, et al, for the Belgian Uro-Oncological Study Group: Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. J Urol 154: 429-434, 1995.
3. Soloway MS, Sharifi R, Wajsman Z, et al, for the Lupron Depot Neoadjuvant Prostate Cancer Study Group: Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. J Urol 154: 424-428, 1995.
4. Labrie F, Dupont A, Cusan L, et al: Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and Lupron®: the first controlled and randomized trial. Clin Invest Med 16: 499-509, 1993.
5. Baert LV, Goethuys HJ, De Ridder DJ, et al: Neoadjuvant treatment before radical prostatectomy decreases the number of positive margins in cT2-T3 but has no impact on PSA progression or survival in cT2-T3. J Urol 159(suppl): 61-65, 1998.
6. Goldenberg SL, Klotz LH, Srigley J, et al, and the Canadian Urologic Oncology Group: Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. J Urol 156: 873-877, 1996.
7. Ballentine Carter H, and Partin AW: Diagnosis and staging of prostate cancer, in Walsh PC, Retik AB, Vaughan ED, et al (Eds): Campbell's Urology. Philadelphia, WB Saunders, 1998, pp 2527.
8. Million RR, Cassisi NJ, and Clark JR: Cancer of the head and neck, in Devita VT Jr, Hellamn S, and Rosenberg SA (Eds): Cancer - Principles and Practice of Oncology. Philadelphia, JB Lippincott, 1989, p 500.
9. Pagano M, and Gauvreau K: Principles of Biostatistics. Belmont, Duxbury Press, 1993, pp 263-265.
10. Cleave ME, Goldenberg SL, Jones EC, et al: Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J Urol 155: 213-219, 1996.
11. Bruchovsky N, Klotz LH, Crook J, et al: A phase 2 study of intermittent androgen suppression in men with a rising serum PSA after radiation for localized prostate cancer. J Urol 159(5): 1287, 1998.
12. Wu HC, Hsieh JT, Cleave ME, et al: Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 57: 406-412, 1994.
13. Foster BA, Gingrich JR, Kwon ED, et al: Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 57: 3325-3330, 1997.